NEPTUNE China Cohort: First-Line Durvalumab plus Tremelimumab versus Chemotherapy in Chinese Patients with Metastatic NSCLC

被引：0
|
作者：
Cheng, Y. [1 ]
Zhou, Q. [2 ]
Han, B. [3 ]
Fan, Y. [4 ]
Shan, L. [5 ]
Chang, J. [6 ,7 ]
Sun, S. [7 ]
Fang, J. [8 ]
Chen, Y. [9 ]
Sun, J. [10 ]
Wu, G. [11 ]
Mann, H. [12 ]
Naicker, K. [12 ]
Shire, N. [13 ]
Mok, T. [14 ]
De Castro, G. [15 ]
机构：
[1] Jilin Canc Hosp, Changchun, Peoples R China
[2] Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Guangdong Lung Canc Inst, Guangzhou, Peoples R China
[3] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China
[4] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[5] Xinjiang Med Univ, Affiliated Canc Hosp, Urumqi, Xinjiang, Peoples R China
[6] Shenzhen Ctr, Chinese Acad Med Sci, Canc Hosp, Shenzhen, Peoples R China
[7] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[8] Peking Univ, Canc Hosp & Inst, Beijing, Peoples R China
[9] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China
[10] Army Med Univ, Inst Canc, Xinqiao Hosp, Chongqing, Peoples R China
[11] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Union, NJ USA
[12] AstraZeneca, Cambridge, England
[13] AstraZeneca, Gaithersburg, MD USA
[14] Chinese Univ Hong Kong, Dept Clin Oncol, State Key Lab South China, Hong Kong, Peoples R China
[15] Inst Canc Estado Sao Paulo, Sao Paulo, Brazil
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
Durvalumab; Tremelimumab; NEPTUNE;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.01-04
引用
收藏
页码：S358 / S358
页数：1
相关论文
共 50 条
  • [41] The Cost-Effectiveness of Sugemalimab Plus Chemotherapy as First-Line Treatment for Metastatic Squamous and Non-squamous NSCLC in China
    Cheng, Rihua
    Zhou, Zhen
    Liu, Qiao
    ADVANCES IN THERAPY, 2023, 40 (10) : 4298 - 4309
  • [42] The Cost-Effectiveness of Sugemalimab Plus Chemotherapy as First-Line Treatment for Metastatic Squamous and Non-squamous NSCLC in China
    Rihua Cheng
    Zhen Zhou
    Qiao Liu
    Advances in Therapy, 2023, 40 : 4298 - 4309
  • [43] Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced NSCLC in Patients aged ≥ 70
    Shen, B.
    Pan, B.
    Wu, Y.
    Shi, L.
    Gao, J.
    Feng, J.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S379 - S379
  • [44] Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC)
    Garon, Edward B.
    Cho, Byoung Chul
    Reinmuth, Niels
    Lee, Ki Hyeong
    Luft, Alexander
    Ahn, Myung-Ju
    Robinet, Gilles
    Le Moulec, Sylvestre
    Natale, Ronald
    Schneider, Jeffrey
    Shepherd, Frances A.
    Garassino, Marina Chiara
    Geater, Sarayut Lucien
    Szekely, Zsolt Papai
    Van Ngoc, Tran
    Liu, Feng
    Scheuring, Urban
    Patel, Nikunj
    Peters, Solange
    Rizvi, Naiyer A.
    CLINICAL LUNG CANCER, 2021, 22 (04) : 301 - +
  • [45] Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous NSCLC That Responded to First-Line Pembrolizumab Plus Chemotherapy
    Hochmair, Maximilian
    Schenker, Michael
    Dols, Manuel Cobo
    Kim, Tae Min
    Ozyilkan, Ozgur
    Smagina, Maria
    Leonova, Viktoriya
    Kato, Terufumi
    Fedenko, Alexander
    De Angelis, Flavia
    Rittmeyer, Achim
    Gray, Jhanelle E.
    Greystoke, Alastair
    Aggarwal, Himani
    Huang, Qinlei
    Zhao, Bin
    Lara-Guerra, Humberto
    Nadal, Ernest
    JOURNAL OF THORACIC ONCOLOGY, 2025, 20 (02) : 203 - 218
  • [46] Tislelizumab plus chemotherapy as first-line treatment for lung cancer in Chinese patients
    Wang, Z.
    Zhao, J.
    Ma, Z.
    Cui, J.
    Shu, Y.
    Liu, Z.
    Cheng, Y.
    Leaw, S.
    Wu, Y.
    Ma, Y.
    Tan, W.
    Wang, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1444 - S1444
  • [47] First-line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component
    Zhou, Yu-Wen
    Long, Yi-Xiu
    Chen, Ye
    Liu, Ji-Yan
    Pu, Dan
    Huang, Jia-Yan
    Bi, Feng
    Li, Qiu
    Gou, Hong-Feng
    Qiu, Meng
    CANCER MEDICINE, 2021, 10 (10): : 3388 - 3402
  • [48] Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC
    Chen, Pingyu
    Wang, Xintian
    Zhu, Shengwen
    Li, Hongchao
    Rui, Mingjun
    Wang, Yingcheng
    Sun, Haikui
    Ma, Aixia
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [49] First-line HDACi plus tislelizumab combined with chemotherapy in advanced NSCLC
    Wang, Lijie
    Gao, Ming
    Yang, Wenyu
    Wang, Chunyu
    Wang, Ting
    Jing, Fangfang
    Ma, Junxun
    Zhang, Fan
    Tao, Haitao
    Hu, Yi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [50] First-Line Durvalumab plus Tremelimumab Treatment for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice
    Fujii, Yasutoshi
    Kawaoka, Tomokazu
    Shirane, Yuki
    Miura, Ryoichi
    Nakahara, Hikaru
    Yamaoka, Kenji
    Uchikawa, Shinsuke
    Fujino, Hatsue
    Ono, Atsushi
    Murakami, Eisuke
    Miki, Daiki
    Hayes, Nelson Clair
    Tsuge, Masataka
    Nakamura, Yuko
    Awai, Kazuo
    Oka, Shiro
    ONCOLOGY, 2024,
12345